Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Tolvaptan Sodium Phosphate for Injection is a selective vasopressin V2-receptor antagonist for intravenous use, administered as a phosphate prodrug that is rapidly converted to the active tolvaptan in vivo. By competitively blocking V2 receptors in the renal collecting duct, it promotes aquaresis, i.e. excretion of electrolyte-free water, thereby raising serum sodium and reducing fluid overload without significant electrolyte loss. The injectable form offers a convenient option when oral administration is not feasible.

This formulation is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, including hyponatremia associated with heart failure and with the syndrome of inappropriate antidiuretic hormone secretion (SIADH), in patients who require intravenous therapy.

Specifications: 8 mg per vial (calculated as tolvaptan), single-dose for intravenous infusion

Packaging: Single-dose glass vial with rubber closure and aluminium seal; carton of 5 vials

Manufactured in full GMP compliance, the product conforms to international quality standards, with stringent control over impurities, particulate matter, stability and endotoxin. Our in-house API production ensures stable supply, competitive pricing, end-to-end quality control and flexible technical support to facilitate your registration and formulation development.

As a selective vasopressin V2-receptor antagonist, it corrects hyponatremia and reduces fluid overload through electrolyte-free water excretion without significant electrolyte loss, offering a valuable option for patients with heart failure and SIADH who cannot take oral therapy.

We are able to supply qualified finished dosage forms, provide technology transfer, and negotiate other flexible cooperation arrangements. Feel free to contact us for  detailed specifications, available documentation, and cooperation terms.